Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Non-Current Deffered Revenue (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue fell 26.24% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, down 26.24% year-over-year, with the annual reading at $1.1 million for FY2025, 26.24% down from the prior year.
  • Non-Current Deffered Revenue hit $1.1 million in Q4 2025 for ARS Pharmaceuticals, down from $1.3 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $3.0 million in Q4 2021 to a low of $1.1 million in Q2 2025.
  • Historically, Non-Current Deffered Revenue has averaged $1.7 million across 4 years, with a median of $1.3 million in 2025.
  • Biggest five-year swings in Non-Current Deffered Revenue: decreased 4.74% in 2022 and later dropped 26.24% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $3.0 million in 2021, then dropped by 4.74% to $2.9 million in 2022, then tumbled by 46.32% to $1.5 million in 2024, then dropped by 26.24% to $1.1 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for SPRY at $1.1 million in Q4 2025, $1.3 million in Q3 2025, and $1.1 million in Q2 2025.